No Data
Volume change rate ranking (9 AM) ~ Ryohin Keikaku, Interaction, ETC are ranked.
In the volume change rate ranking, by comparing the average volume over the last 5 days with the volume on the day of the release, it is possible to understand the trends of market participants' interests, etc. ■ Volume Change Rate Top [As of January 14, 9:32] (Comparing with the average volume over the last 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <2624> iF225 Year 4 17213107185.08 289.48%-0.0101% <9058> To
Emerging Markets Outlook: If the Growth Market 250 Index ETF breaks through the 200-day line, investor sentiment may improve.
■ During the year-end and New Year period (December 30, 2024 - January 10, 2025), the Emerging Markets saw mixed results in stock selection. During the same period, while the Nikkei Index decreased by -2.71%, the Growth Market Index increased by +0.40%, and the Growth Market 250 Index was nearly flat at -0.02%, showing strength compared to the Main Board. In the Tokyo market, the decline in US stocks had an impact, leading to limited trading activity in leading Large Cap stocks, resulting in a decrease in the Nikkei Index towards the weekend. On the other hand, individual...
The Tokyo Stock Exchange Growth Index has slightly declined, briefly rising into positive territory but then losing momentum.
Tokyo Stock Exchange Growth Market Index 825.08 -0.46 / Volume 0.1 billion 85.09 million shares / Trading value 134.6 billion yen. Tokyo Stock Exchange Growth Market 250 Index 643.42 -0.25 / Volume 0.1 billion 8.41 million shares / Trading value 101.2 billion yen. Today's growth market saw a slight downturn in both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index, with 218 stocks rising, 349 stocks declining, and 37 unchanged. Today's growth market experienced a complicated interplay of buying and selling.
Stocks that hit the upper or lower limit in the afternoon session.
■ Limit up <190A> Chordia Therapeutics <4889> Renascience <5247> BTM <7112> Cube <7359> Tokyo Communications Group ■ Limit down <269A> Sapheet <303A> visumo <4736> Japan Rad <4935> Liberta <6864> NF Holdings <8783> GFA * Includes temporary limit up and down (indicative price).
Lena Science is trading at the upper limit, showing significant response in the Phase 1 trial licensed to them.
Lenna Science <4889.T> ended the morning session of trading at 382 yen, a fluctuation of 80 yen from the previous day at the stop-high buy interest. At 8:30 AM on the 9th, the company announced that it has signed a licensing agreement granting exclusive rights to the US Eirion Therapeutics (Eirion Inc.) for 'RS5441' (topical and oral medication), and reported the results of the first phase clinical trial for the topical drug 'ET-02' containing 'RS5441' for male pattern baldness and age-related hair loss.
Renascient has hit the upper limit on trading due to favorable results in a phase 1 clinical trial for male pattern baldness, ETC.
Renascience <4889.T> is up 80 yen compared to the previous day, with a stop-limit buy indication at 382 yen. Before the market opened on the 9th, it was announced that the phase 1 clinical trial of the external drug ET-02 (with RS5441 as the main ingredient) for male pattern baldness and age-related hair loss received favorable results, which was well-received. The company signed a licensing agreement granting exclusive implementation rights for RS5441 (an external and oral drug) to Eirion Therapeutics, Inc. (Eirion) in October 2016.